[{"id":"3fe15ba6-c8bd-43a0-9070-1c6451e7aaf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310879","created_at":"2021-01-18T16:21:04.198Z","updated_at":"2024-07-02T16:35:20.810Z","phase":"Phase 2","brief_title":"Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6","source_id_and_acronym":"NCT03310879","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/21/2017","start_date":" 11/21/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-02-06"},{"id":"266a2712-9c1f-4bc2-b88c-002f9d951d7d","acronym":"GOG-3039","url":"https://clinicaltrials.gov/study/NCT04393285","created_at":"2023-12-13T16:16:37.842Z","updated_at":"2024-07-02T16:35:26.346Z","phase":"Phase 2","brief_title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","source_id_and_acronym":"NCT04393285 - GOG-3039","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20","pipe":" | ","alterations":" CCND1 expression • CCND1 mutation","tags":["ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/10/2020","start_date":" 10/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-13"},{"id":"b39d6f05-f231-4745-aadd-73899fae2d7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04594005","created_at":"2021-01-19T20:29:03.455Z","updated_at":"2024-07-02T16:35:34.460Z","phase":"Phase 1/2","brief_title":"CDK4/6 Tumor, Abemaciclib, Paclitaxel","source_id_and_acronym":"NCT04594005","lead_sponsor":"Yonsei University","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/25/2021","start_date":" 02/25/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2023-10-06"},{"id":"6160affe-41bc-4a57-bb71-a5426702805e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990778","created_at":"2021-08-04T13:53:08.284Z","updated_at":"2024-07-02T16:36:15.692Z","phase":"Phase 2","brief_title":"Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04990778","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1 • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation","tags":["CCND1 • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • eprenetapopt (APR-246)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2022-03-10"},{"id":"de3ecf6b-3b4c-409e-bd4d-5f880ce8753e","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT02187783","created_at":"2021-01-18T10:12:32.699Z","updated_at":"2024-07-02T16:36:57.957Z","phase":"Phase 2","brief_title":"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)","source_id_and_acronym":"NCT02187783 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDKN2A • CCND1 • CDK4 • CDK6 • CCND3","pipe":" | ","alterations":" CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification","tags":["CDKN2A • CCND1 • CDK4 • CDK6 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 01/17/2018","primary_completion_date":" 01/17/2018","study_txt":" Completion: 01/17/2018","study_completion_date":" 01/17/2018","last_update_posted":"2019-07-18"}]